MX2023002455A - Células inmunitarias modificadas con receptores cebadores. - Google Patents
Células inmunitarias modificadas con receptores cebadores.Info
- Publication number
- MX2023002455A MX2023002455A MX2023002455A MX2023002455A MX2023002455A MX 2023002455 A MX2023002455 A MX 2023002455A MX 2023002455 A MX2023002455 A MX 2023002455A MX 2023002455 A MX2023002455 A MX 2023002455A MX 2023002455 A MX2023002455 A MX 2023002455A
- Authority
- MX
- Mexico
- Prior art keywords
- priming
- receptors
- immune cells
- engineered immune
- cells
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title 1
- 230000037452 priming Effects 0.000 title 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se proporcionan métodos para editar genéticamente células con plantillas de ADN grandes mediante el uso de un método de edición no viral. En la presente también se proporcionan células que comprenden al menos una plantilla de ADN grande insertada de forma no viral en una región objetivo del genoma de la célula.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063072080P | 2020-08-28 | 2020-08-28 | |
PCT/US2021/048066 WO2022047237A1 (en) | 2020-08-28 | 2021-08-27 | Engineered immune cells with priming receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002455A true MX2023002455A (es) | 2023-05-16 |
Family
ID=80352430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002455A MX2023002455A (es) | 2020-08-28 | 2021-08-27 | Células inmunitarias modificadas con receptores cebadores. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230340409A1 (es) |
EP (1) | EP4204575A1 (es) |
JP (1) | JP2023543137A (es) |
KR (1) | KR20230083275A (es) |
CN (1) | CN116529364A (es) |
AU (1) | AU2021334366A1 (es) |
CA (1) | CA3191148A1 (es) |
IL (1) | IL300994A (es) |
MX (1) | MX2023002455A (es) |
WO (1) | WO2022047237A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023205724A2 (en) * | 2022-04-20 | 2023-10-26 | Arsenal Biosciences, Inc. | Cells comprising a suppressor of gene expression and/or a synthetic pathway activator and/or an inducible payload |
WO2023225059A2 (en) * | 2022-05-17 | 2023-11-23 | Arsenal Biosciences, Inc. | Systems of engineered receptors targeting psma and ca9 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112543650A (zh) * | 2018-04-24 | 2021-03-23 | 利甘达尔股份有限公司 | 基因组编辑的方法和组合物 |
-
2021
- 2021-08-27 MX MX2023002455A patent/MX2023002455A/es unknown
- 2021-08-27 AU AU2021334366A patent/AU2021334366A1/en active Pending
- 2021-08-27 CN CN202180073716.2A patent/CN116529364A/zh active Pending
- 2021-08-27 KR KR1020237010538A patent/KR20230083275A/ko unknown
- 2021-08-27 CA CA3191148A patent/CA3191148A1/en active Pending
- 2021-08-27 WO PCT/US2021/048066 patent/WO2022047237A1/en active Application Filing
- 2021-08-27 EP EP21862873.3A patent/EP4204575A1/en active Pending
- 2021-08-27 IL IL300994A patent/IL300994A/en unknown
- 2021-08-27 JP JP2023514105A patent/JP2023543137A/ja active Pending
-
2023
- 2023-02-27 US US18/114,981 patent/US20230340409A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4204575A1 (en) | 2023-07-05 |
AU2021334366A9 (en) | 2024-06-13 |
CA3191148A1 (en) | 2022-03-03 |
JP2023543137A (ja) | 2023-10-13 |
KR20230083275A (ko) | 2023-06-09 |
CN116529364A (zh) | 2023-08-01 |
IL300994A (en) | 2023-04-01 |
WO2022047237A1 (en) | 2022-03-03 |
AU2021334366A1 (en) | 2023-05-11 |
US20230340409A1 (en) | 2023-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002455A (es) | Células inmunitarias modificadas con receptores cebadores. | |
CO2021006363A2 (es) | Composiciones y métodos para la expresión de transgenes a partir de un locus de albúmina | |
EA202191463A1 (ru) | Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде | |
GB2573664A (en) | Viral methods of T cell therapy | |
MX2018001617A (es) | Composiciones de crispr-cas9 diseñados y metodos de uso. | |
CO2019013821A2 (es) | Materiales y métodos para modificar células por ingeniería genética y usos de los mismos en inmunooncología | |
CL2019001473A1 (es) | Edición génica e inducción de haploides simultáneas. | |
MX2023001088A (es) | Bibliotecas de transcriptomas de celulas individuales de alto rendimiento y metodos de fabricacion y uso. | |
WO2019089884A3 (en) | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy | |
MX2018013445A (es) | Celulas diseñadas geneticamente y metodos para obtener las mismas. | |
MX2021004214A (es) | Composiciones y metodos de inmunoterapia. | |
RU2016101246A (ru) | Направленная интеграция | |
RU2016120636A (ru) | Оптимальные локусы сои | |
ZA202206200B (en) | Method for creating new gene in organism and use thereof | |
MX2021013219A (es) | Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos. | |
MX2022007575A (es) | Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos. | |
NZ762361A (en) | Target sequence specific alteration technology using nucleotide target recognition | |
BR112021014645A2 (pt) | Método de edição de genes | |
MX2023007524A (es) | Composiciones y metodos para edicion epigenetica. | |
BR112019005605A2 (pt) | métodos para modificar o genoma (nuclear) de uma célula vegetal e um gene epsps endógeno ou para produzir uma célula vegetal ou para testar a eficiência de edição de genoma, bactéria, e, vetor | |
MX2021004455A (es) | Composiciones y métodos para administrar transgenes. | |
WO2015157431A3 (en) | Selective advantage in fermentation | |
MX2022007107A (es) | Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas. | |
MX2021014528A (es) | Metodos y composiciones para generar alelos dominantes usando edicion del genoma. | |
GB2600568A8 (en) | Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing |